Literature DB >> 7904984

Headaches and women: treatment of the pregnant and lactating migraineur.

S D Silberstein1.   

Abstract

Migraine is a hormonally sensitive episodic headache disorder which may worsen during the first trimester, but usually improves during later pregnancy. Its treatment can be difficult because of the risks of injury to the fetus and newborn. These risks include teratogenicity, embryo mortality, fetal growth abnormalities, and perinatal effect. This paper reviews the effects of drugs on the fetus and newborn, their FDA classification, and their use during both pregnancy and lactation. Specific recommendations are given.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7904984     DOI: 10.1111/j.1526-4610.1993.hed3310533.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  6 in total

Review 1.  Migraine during pregnancy: options for therapy.

Authors:  Anthony W Fox; Merle L Diamond; Egilius L H Spierings
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 2.  The neurology of pregnancy.

Authors:  G V Sawle; M M Ramsay
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-06       Impact factor: 10.154

Review 3.  Migraine in pregnancy: what are the safest treatment options?

Authors:  V Pfaffenrath; M Rehm
Journal:  Drug Saf       Date:  1998-11       Impact factor: 5.606

Review 4.  Updated Evaluation of IV Dihydroergotamine (DHE) for Refractory Migraine: Patient Selection and Special Considerations.

Authors:  Rafia Shafqat; Yadira Flores-Montanez; Victoria Delbono; Stephanie J Nahas
Journal:  J Pain Res       Date:  2020-04-30       Impact factor: 3.133

Review 5.  Safe prescribing practices in pregnancy and lactation.

Authors:  Wendy F Hansen; Anne E Peacock; Jerome Yankowitz
Journal:  J Midwifery Womens Health       Date:  2002 Nov-Dec       Impact factor: 2.388

6.  Acute migraine: Current treatment and emerging therapies.

Authors:  Arun A Kalra; Debra Elliott
Journal:  Ther Clin Risk Manag       Date:  2007-06       Impact factor: 2.423

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.